5 results about "Procaine" patented technology

This invention discloses a rapid mass spectrometry method and kit for the simultaneous detection of multiple components in body fluids, belonging to the field of biological detection and identification technology. It can rapidly detect trace compounds such as drugs and biomarkers in complex biological samples. This kit mainly utilizes loaded functional materials to achieve extraction and enrichment of target analytes and is equipped with a quick connector for coupling with a detector to achieve rapid detection. Compared with traditional methods, the significant advantages of the method established by this kit are that it does not require complex sample pretreatment, allows for micro-quantitative sampling, requires small sample volumes, facilitates convenient storage of biological samples, is easy to operate, does not require specialized technical personnel, and enables rapid on-site detection when coupled with portable mass spectrometry. This kit has been successfully used for the detection of quinine, procainamide hydrochloride, atenolol, and nortriptyline in complex samples such as blood and serum, and has significant clinical and economic value.

The invention relates to the technical field of pharmaceutical co-crystals, and particularly discloses a benzocain-3, 5-dihydroxybenzoic acid co-crystal as well as a preparation method and application of the benzocain-3, 5-dihydroxybenzoic acid co-crystal. The benzocain-3, 5-dihydroxy benzoic acid eutectic crystal provided by the invention comprises benzocaine and 3, 5-dihydroxy benzoic acid, and the molar ratio of the benzocaine to the 3, 5-dihydroxy benzoic acid is 1: (0.8-1.2). According to the benzocain-3, 5-dihydroxybenzoic acid eutectic crystal prepared by the invention, the equilibrium solubility, antibacterial property and stability of benzocaine can be effectively improved; the preparation method of the benzocain-3, 5-dihydroxy benzoic acid eutectic crystal provided by the invention is simple in process, easy to control the crystallization process and good in reproducibility, and has relatively good economical efficiency and industrial production value.

The present invention relates to a contour injection composition, and more specifically, is characterized by an injection composition comprising a solvent, aminophylline, procaine, epinephrine, and hyaluronidase, the injection composition comprising, on the basis of the entire composition, 500 to 700 IU units hyaluronidase, and 0.05 to 0.15% (w / v) aminophylline, 0.01 to 0.03% (w / v) procaine, 0.001 to 0.006% (w / v) epinephrine, and the remainder the solvent, wherein the solvent is half saline and distilled water. According to the present invention, the injection composition has excellent fat decomposition and fat destruction effects and cellulite reduction effect, as well as effect in improving a circulation function, thereby reducing subcutaneous fat in a desired area, and having the advantages not only of improving body and facial lines by improving elasticity, but also not causing side effects such as redness, itchiness, swelling, skin depression, and skin sagging.

The invention belongs to the technical field of anesthesia dressings, and discloses a pharmaceutical composition for local anesthesia and a preparation method thereof. The pharmaceutical composition for local anesthesia is prepared from the following components: 10 to 20 parts of procaine, 0.9 to 1.5 parts of bergenin, 3 to 5 parts of a stabilizer, 5 to 10 parts of a surfactant, 1 to 3 parts of sodium carboxymethyl cellulose and 70 to 80 parts of normal saline. When the pharmaceutical composition for local anesthesia is applied to the skin, the anesthetic effect of the drug procaine can be remarkably enhanced, the local anesthesia duration can be prolonged, the clinical administration frequency can be reduced, and the stability of the drug procaine can be improved. The pharmaceutical composition for local anesthesia is safe and non-irritant to skin, and has a good application prospect.

This invention belongs to the field of pharmaceutical synthesis technology, specifically relating to a method for preparing chloroprocaine hydrochloride and its intermediates, and their applications. The invention uses 2-chloro-4-nitrobenzoic acid and N,N-diethylethanolamine as starting materials, and prepares nitrochlorocaine via sulfuric acid-catalyzed esterification. Nitrochlorocaine is then reduced with thiourea dioxide to obtain crude chloroprocaine. The crude chloroprocaine is then salted in hydrochloric acid and ethanol, crystallized, and dried to obtain the final product, chloroprocaine hydrochloride. This method features low cost, high product quality, high yield, simple process, high production capacity, environmental friendliness, and suitability for industrial production, thus possessing significant industrialization value.